Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanylate cyclase 1 soluble subunit beta-1 is a catalytic subunit of soluble guanylate cyclase (sGC), an enzyme critical for nitric oxide (NO) signaling in human physiology. It forms a heterodimer with the alpha subunit (typically sGCα1), and together this enzyme acts as the primary cellular receptor for nitric oxide. Upon binding NO, the heme-containing domain in the beta-1 subunit facilitates a conformational change, dramatically increasing sGC's catalytic efficiency to convert GTP to cGMP, a second messenger that mediates smooth muscle relaxation, vasodilation, neurotransmission, and inhibition of platelet aggregation. Dysregulation or dysfunction of this enzyme system is relevant to cardiovascular, neurodegenerative, and proliferative diseases. It is a validated drug target for approved vasodilators and sGC stimulators.
Drugs stimulate guanylate cyclase activity, increasing cGMP production by mimicking or enhancing the action of nitric oxide or directly activating the enzyme
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanylate cyclase 1 soluble subunit beta-1 (GUCY1B1).